US FDA Won't Budge On Nitrosamines Compliance Despite Complaints Of Possible Drug Shortages

Chemcial diagram of probable carcinogen N-nitrosodimethylamine linked to FDA's investigation of nitrosamines in drugs that began after an independent testing firm in 2019 submitted petition showing it in OTC heartburn remedies with ranitidine as an active ingredient. • Source: Alamy
HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Regulation

More from Policy & Regulation